Antibe Therapeutics Releases Secondary Endpoint Data for Lead Drug

Ontario Industry Updates
Written by obio

 Antibe Therapeutics released positive secondary endpoint data from the recent Phase 2B Gastrointestinal safety study for its lead drug, ATB-346. These results are consistent with the primary endpoint data, previously released in March 2018. 

Click here to see the press release. 

obio
Previous

Investor Spotlights: Amgen and AmorChem - JLABS Toronto
Next

Reviewing 'Formulating a Non-Dilutive Fundraising Strategy', Part 2 of OBIO's 'Building Your Early-Stage Strategy Toolbox' Event